<DOC>
	<DOCNO>NCT02263105</DOCNO>
	<brief_summary>Currently , prognosis recurrent high-grade glioma still dismal standard treatment protocol establish . Cisplatin ( CDDP ) , recommend National Comprehensive Cancer Network ( NCCN ) chemotherapeutic agent salvage treatment recurrent high-grade glioma , show reduce O6-alkylguanine DNA-alkyl transferase ( AGAT ) activity potentially capable enhance antitumor effect temozolomide ( TMZ ) . Compared standard 5-day TMZ regimen , alternate weekly regimen deliver prolong exposure TMZ may lead high cumulative dos , may deplete O6-methylguanine DNA methyltransferase ( MGMT ) , thus reduce resistance tumor cell TMZ . The investigator therefore initiate single-arm Phase II study evaluate efficacy tolerability CDDP plus alternate weekly TMZ regimen patient recurrent high-grade glioma .</brief_summary>
	<brief_title>Efficacy Tolerability Cisplatin Plus Alternating Weekly Temozolomide Recurrent High-grade Gliomas</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Histological diagnosis primary tumor highgrade glioma ( WHO III IV ) All patient complete radiation therapy primary glioma . MRI show unequivocal evidence tumor recurrence progression . The time enrol 90 day radiation therapy . Written inform consent Eastern Cooperative Oncology Group ( ECOG ) score : 02 The patient recurrent gliomas treat without dosedense TMZ therapy enrollment . Surgical intervention recurrent gliomas permit patient residual tumor permit Abnormal function liver renal ( value 1.5 fold normal upper limit ) Blood routing : Hb &lt; 90g/L , absolute neutrophil countâ‰¤1.5*10^9/L , platelet &lt; 100*10^9/L Pregnant lactate woman Allergic administer drug Radiation therapy previous 90 day enrollment The patient recurrent gliomas treat dosedense TMZ therapy enrollment . Acute infection need antibiotic intravenously Participation clinical trial 90 day enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>recurrent high-grade glioma</keyword>
	<keyword>cisplatin ( CDDP )</keyword>
	<keyword>temozolomide ( TMZ )</keyword>
</DOC>